Article By:
Lorimer Wilson
Sunday, July 14, 2024 11:17 AM EDT
The 10 clinical-stage AI-focused and psychedelic compound-based drug discovery companies in our Clinical-Stage BioTech Drug Stocks Portfolio are UP 12.8% MTD after having gone DOWN 13.2%, on average, in June and are now UP 13.8%, on average, YTD.
The 8 Largest Psychedelic Compounds-Based Drug Stocks: A Financial Assessment
I like $CMPS and $GHRS.